Certainly there are rising acuities across the Care Continuum. We, you know, see those as positive demographics for our business, ageing population, complex co-morbidities and obesity. And then, again, you know, we’re addressing those through daily driven clinical evidence and increasing R&D investment as we talked about at our Investor Day, and I’ll touch on that a little more in a minute. We’re looking to increase our level of R&D investment, combination of new products to meet some of these needs and also developing even more clinical evidence to support our value proposition.
Certainly, a care giver safety as a major issue and you know, that – its impact on satisfaction and turnover. We have products that improve our genomics. And certainly, can support reduction in injuries, especially back injuries etcetera through some of our aims to mobility. And both our lists and our frame businesses both help support that area.
Emerging populations, requiring increased access to care. You know, certainly we are focused not just in the developed world, North America, Western Europe, but we recognize the opportunities and the needs to develop region specific products and that are certainly things that we’re working on within our R&D investments as well.
And then, increased movement of healthcare outside the Acute Setting and into the Post-Acute Setting, be it in the extended care or home care, is certainly a trend that we see and one that we’re looking to meet. We do have product offering that’s been in the Care Continuum today. And we’re certainly looking to strengthen that position.Read the rest of this transcript for free on seekingalpha.com